ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify cryptic binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets.

ENSEM has assembled an experienced leadership team with proven track records across the continuum of R&D disciplines: from computer-aided drug design enhanced by AI-based technology, biophysics & structure biology, chemistry, and DMPK, to biochemistry and biology.

ETX-197: A Potential Best-In-Class Oral CDK2 Inhibitor ETX-636: A Differentiated Approach to Target Mutant PI3Kα Discovery Programs We have a number of early-stage discovery programs at various stages of maturity launched with our Kinetic Ensemble® platform. With an initial focus on oncology, our team is looking at a variety of different exploratory and novel targets.

Substantial challenges exist in small molecule drug discovery in high-value but difficult-to-drug targets Kinetic Ensemble®, ENSEM’s deep learning AI platform, addresses these challenges and has enabled a clinical-stage proprietary precision medicine pipeline in three years

ENSEM is advancing a pipeline with potential best-in-class orally bioavailable molecules for patients with unmet needs in oncology. Utilizing our Kinetic Ensemble ® platform, we have generated three pipeline programs to date, with the potential to expand.

Daliya Banerjee Ph.D. (Lead author) Ensem Therapeutics [email protected] www.Ensemtx.com Figure 3. ETX-197 is a Potent and Selective, Orally Bioavailable Inhibitor of CDK2 Kinase Activity ETX-197 shows improved potency and selectivity over PF07104091 in biochemical, biophysical and cellular assays Biochemical activityb (IC50; nM ...

2023年2月11日 · January 27, 2025 ENSEM Presentation at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025

Ensem Therapeutics [email protected] Headquarters880 Winter StreetSuite 1003Waltham MA, 02451 Shanghai Site103 Cailun RoadRoom 201, Building APudong, Shanghai, China Headquarters880 Winter Street,Suite 1003,Waltham MA, 02451 Shanghai Site103 Cailun Road,Room 201, Building A,Pudong, Shanghai, China

2023年6月5日 · Ensem Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets

ENSEM integrates computational and AI deep learning methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on high-value and difficult-to-drug targets.